Tapeworm infection

White AC Jr, Coyle CM, Rajshekhar V, et al. Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2018 Apr 3;66(8):e49-75.Full text  Abstract

World Health Organization. ​WHO guidelines on management of Taenia solium neurocysticercosis. Sep 2021 [internet publication].Full text

Del Brutto OH, Nash TE, White AC Jr, et al. Revised diagnostic criteria for neurocysticercosis. J Neurol Sci. 2017 Jan 15;372:202-10.Full text  Abstract

Centers for Disease Control and Prevention. Parasites - taeniasis: resources for health professionals. Oct 2020 [internet publication].Full text

1. Schantz PM, Kern P, Brunetti R. Echinococcus. In: Guerrant RL, Walker DH, Weller PF, eds. Tropical infectious diseases: principles, pathogens and practice. 1st ed. Oxford, UK: Churchill Livingstone; 2005:1304-26.

2. Wittner M, Tanowitz HB, White AC. Taenia and other tapeworms. In: Guerrant RL, Walker DH, Weller PF, eds. Tropical infectious diseases: principles, pathogens and practice. 1st ed. Oxford, UK: Churchill Livingstone; 2005:1327-40.

3. Hernández-Orts JS, Scholz T, Brabec J, et al. High morphological plasticity and global geographical distribution of the Pacific broad tapeworm Adenocephalus pacificus (syn. Diphyllobothrium pacificum): molecular and morphological survey. Acta Trop. 2015 Sep;149:168-78. Abstract

4. Garcia HH, del Brutto OH. Taenia solium cysticercosis. Inf Dis Clin North Am. 2000 Mar;14(1):97-119. Abstract

5. Verastegui M, Gilman RH, Garcia HH, et al. Prevalence of antibodies to unique Taenia solium onchosphere antigens in Taeniasis and human and porcine cysticercosis. Am J Trop Med Hyg. 2003 Oct;69(4):438-44.Full text  Abstract

6. Gonzalez AE, Garcia HH, Gilman RH, et al. Control of Taenia solium. Acta Trop. 2003 Jun;87(1):103-9. Abstract

7. Zoli A, Shey-Njila O, Assana E, et al. Regional status, epidemiology and impact of Taenia solium cysticercosis in Western and Central Africa. Acta Trop. 2003 Jun;87(1):35-42. Abstract

8. Braae UC, Thomas LF, Robertson LJ, et al. Epidemiology of Taenia saginata taeniosis/cysticercosis: a systematic review of the distribution in the Americas. Parasit Vectors. 2018 Sep 20;11(1):518.Full text  Abstract

9. O'Neal SE, Flecker RH. Hospitalization frequency and charges for neurocysticercosis, United States, 2003-2012. Emerg Infect Dis. 2015 Jun;21(6):969-76.Full text  Abstract

10. World Health Organization. Taeniasis/cysticercosis: fact sheet. Jan 2022 [internet publication].Full text

11. Laranjo-González M, Devleesschauwer B, Trevisan C, et al. Epidemiology of taeniosis/cysticercosis in Europe, a systematic review: Western Europe. Parasit Vectors. 2017 Jul 21;10(1):349.Full text  Abstract

12. Scholz T, Garcia HH, Kuchta R, et al. Update on the human broad tapeworm (genus diphyllobothrium), including clinical relevance. Clin Microbiol Rev. 2009 Jan;22(1):146-60.Full text  Abstract

13. Khalil HM, el Shimi S, Sarwat MA, et al. Recent study of Hymenolepis nana infection in Egyptian children. J Egypt Soc Parasitol. 1991 Apr;21(1):293-300. Abstract

14. Aria HP. Biology of the tapeworm Hymenolepis diminuta. New York, NY: Academic Press; 1980.

15. Biswas H, Arora RR, Sehgal S. Epidemiology of Hymenolepis nana infections in a selected rural community. J Commun Dis. 1978;10(3):170-4.

16. Mason PR, Patterson BA. Epidemiology of Hymenolepis nana infections in primary school children in urban and rural communities in Zimbabwe. J Parasitol. 1994 Apr;80(2):245-50. Abstract

17. World Health Organization. Echinococcosis: fact sheet​. May 2021 [internet publication].Full text

18. Del Brutto OH, Sotelo J, Roman GC. Neurocysticercosis: a clinical handbook. Lisse, The Netherlands: Swets and Zeitlinger; 1998.

19. Bandres JC, White AC Jr, Samo T, et al. Extraparenchymal neurocysticercosis: report of five cases and review of management. Clin Infect Dis. 1992 Nov;15(5):799-811. Abstract

20. Garcia HH, Wittner M, Coyle CM, et al. Cysticercosis. In: Guerrant RL, Walker DH, Weller PF, eds. Tropical infectious diseases: principles, pathogens and practice. 1st ed. Oxford, UK: Churchill Livingstone; 2005:1289-303.

21. Elmonir W, Elaadli H, Amer A, et al. Prevalence of intestinal parasitic infections and their associated risk factors among preschool and school children in Egypt. PLoS One. 2021;16(9):e0258037.Full text  Abstract

22. Gelaw A, Anagaw B, Nigussie B, et al. Prevalence of intestinal parasitic infections and risk factors among schoolchildren at the University of Gondar Community School, Northwest Ethiopia: a cross-sectional study. BMC Public Health. 2013 Apr 5;13:304.Full text  Abstract

23. Openshaw JJ, Medina A, Felt SA, et al. Prevalence and risk factors for Taenia solium cysticercosis in school-aged children: a school based study in western Sichuan, People's Republic of China. PLoS Negl Trop Dis. 2018 May;12(5):e0006465.Full text  Abstract

24. Pan American Health Organization. Guideline for preventive chemotherapy for the control of Taenia solium taeniasis. S​ep 2021 [internet publication].Full text

25. Garcia HH, Gonzalez AE, Tsang VC, et al. Elimination of Taenia solium transmission in northern Peru. N Engl J Med. 2016 Jun 16;374(24):2335-44.Full text  Abstract

26. World Health Organization. Early detection and management of neurological serious adverse events in relation to the administration of anthelminthic medicines to people with asymptomatic neurocysticercosis. Sep 2023 [internet publication].Full text

27. Di Lernia V, Ricci C, Albertini G. Skin eruption associated with Hymenolepis nana infection. Int J Dermatol. 2004 May;43(5):357-9. Abstract

28. Muehlenbachs A, Bhatnagar J, Agudelo CA, et al. Malignant transformation of Hymenolepis nana in a human host. N Engl J Med. 2015 Nov 5;373(19):1845-52.Full text  Abstract

29. Conn DB. Malignant transformation of Hymenolepis nana in a human host. N Engl J Med. 2016 Mar 31;374(13):1293-4. Abstract

30. Saeedan MB, Aljohani IM, Alghofaily KA, et al. Thoracic hydatid disease: a radiologic review of unusual cases. World J Clin Cases. 2020 Apr 6;8(7):1203-12.Full text  Abstract

31. Cuetter AC, Garcia-Bobadilla J, Guerra LG, et al. Neurocysticercosis: focus on intraventricular disease. Clin Infect Dis. 1997 Feb;24(2):157-64. Abstract

32. ​Department of Health, Victoria State Government, Australia. Taeniasis (tapeworm)​. Oct 2015 [internet publication].Full text

33. White AC Jr, Coyle CM, Rajshekhar V, et al. Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2018 Apr 3;66(8):e49-75.Full text  Abstract

34. Centers for Disease Control and Prevention. CDC Yellow Book section 5: travel-associated infections & diseases - parasitic. Taeniasis. May 2023 [internet publication].Full text

35. Proaño-Navarez JV, Meza-Lucas A, Mata-Ruiz O, et al. Laboratory diagnosis of human neurocysticercosis: double-blind comparison of enzyme-linked immunosorbent assay and electroimmunotransfer blot assay. J Clin Microbiol Rev. 2002 Jun;40(6):2115-8.Full text  Abstract

36. Mejia R, Nutman TB. Evaluation and differential diagnosis of marked, persistent eosinophilia. Semin Hematol. 2012 Apr;49(2):149-59.Full text  Abstract

37. Groove D. A history of human helminthology. Wallingford, UK: CAB International; 1990.

38. WHO Informal Working Group. International classification of ultrasound images in cystic echinococcosis for application in clinical and field epidemiological settings. Acta Trop. 2003 Feb;85(2):253-61. Abstract

39. World Health Organization. ​WHO guidelines on management of Taenia solium neurocysticercosis. Sep 2021 [internet publication].Full text

40. Webb CM, White AC Jr. Update on the diagnosis and management of neurocysticercosis. Curr Infect Dis Rep. 2016 Dec;18(12):44. Abstract

41. Schantz PM, Kern P, Brunetti R. Echinococcus. In: Guerrant RL, Walker DH, Weller PF, eds. Tropical infectious diseases: principles, pathogens and practice. 1st ed. Oxford, UK: Churchill Livingstone; 2005:1304-26.

42. Garcia HH, Gilman R, Martinez M, et al. Cysticercosis as a major cause of epilepsy in Peru. Lancet. 1993 Jan 23;341(8839):197-200. Abstract

43. Del Brutto OH, Nash TE, White AC Jr, et al. Revised diagnostic criteria for neurocysticercosis. J Neurol Sci. 2017 Jan 15;372:202-10.Full text  Abstract

44. Carpio A, Fleury A, Romo ML, et al. New diagnostic criteria for neurocysticercosis: reliability and validity. Ann Neurol. 2016 Sep;80(3):434-42.Full text  Abstract

45. Centers for Disease Control and Prevention. CDC Yellow Book section 5: travel-associated infections & diseases - parasitic​. Cysticercosis. May 2023 [internet publication].Full text

46. White AC Jr, Garcia HH. Updates on the management of neurocysticercosis. Curr Opin Infect Dis. 2018 Oct;31(5):377-82. Abstract

47. Centers for Disease Control and Prevention. Parasites - taeniasis: resources for health professionals. Oct 2020 [internet publication].Full text

48. Centers for Disease Control and Prevention. Parasites - cysticercosis: resources for health professionals. Oct 2020 [internet publication].Full text

49. Proaňo JV, Madrazo I, Avelar F, et al. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med. 2001 Sep 20;345(12):879-85.Full text  Abstract

50. Mitre E, Talaat KR, Sperling MR, et al. Methotrexate as a corticosteroid-sparing agent in complicated neurocysticercosis. Clin Infect Dis. 2007 Feb 15;44(4):549-53. Abstract

51. Garcia HH, Lescano AG, Gonzales I, et al. Cysticidal efficacy of combined treatment with praziquantel and albendazole for parenchymal brain cysticercosis. Clin Infect Dis. 2016 Jun 1;62(11):1375-9. Abstract

52. Garcia HH, Gonzales I, Lescano AG, et al. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis. 2014 Aug;14(8):687-95. Abstract

53. Monk E, Abba K, Ranganathan L. Anthelmintics for people with neurocysticercosis. Cochrane Database Syst Rev. 2021 Jun 1;6(6):CD000215.Full text  Abstract

54. Walton D, Castell H, Collie C, et al. Antiepileptic drugs for seizure control in people with neurocysticercosis. Cochrane Database Syst Rev. 2021 Nov 1;11(11):CD009027.Full text  Abstract

55. Garcia HH, Gonzales I, Lescano AG, et al. Enhanced steroid dosing reduces seizures during antiparasitic treatment for cysticercosis and early after. Epilepsia. 2014 Sep;55(9):1452-9.Full text  Abstract

56. Koul PA, Singh AA, Ahanger AG, et al. Optimal duration of preoperative anti-helminthic therapy for pulmonary hydatid surgery. ANZ J Surg. 2010 May;80(5):354-7. Abstract

57. Khuroo MS, Wani NA, Javid G, et al. Percutaneous drainage compared with surgery for hepatic hydatid cysts. N Engl J Med. 1997 Sep 25;337(13):881-7.Full text  Abstract

58. Smego RA Jr, Bhatti S, Khaliq AA, et al. Percutaneous aspiration-injection-reaspiration drainage plus albendazole or mebendazole for hepatic cystic echinococcosis: a meta-analysis. Clin Infect Dis. 2003 Oct 15;37(8):1073-83. Abstract

59. The Medical Letter. Drugs for parasitic infections. New Rochelle, NY: The Medical Letter; 2007.

60. An G, Murry DJ, Gajurel K, et al. Pharmacokinetics, safety, and tolerability of oxfendazole in healthy volunteers: a randomized, placebo-controlled first-in-human single-dose escalation study. Antimicrob Agents Chemother. 2019 Apr;63(4):e02255-18.Full text  Abstract

61. Bach T, Galbiati S, Kennedy JK, et al. Pharmacokinetics, safety, and tolerability of oxfendazole in healthy adults in an open-label phase 1 multiple ascending dose and food effect study. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01018-20.Full text  Abstract

62. WHO-Informal Working Group on Echinococcosis. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans​. Nov 2009 [internet publication].Full text